PapersFlow Research Brief
Amyloidosis: Diagnosis, Treatment, Outcomes
Research Guide
What is Amyloidosis: Diagnosis, Treatment, Outcomes?
Amyloidosis: Diagnosis, Treatment, Outcomes refers to the study of diseases caused by misfolded protein aggregates forming amyloid fibrils, focusing on diagnostic methods, therapeutic interventions such as RNAi therapy, and prognostic factors, particularly in transthyretin-related cardiac amyloidosis and familial amyloid polyneuropathy.
The field encompasses 54,889 papers on molecular mechanisms, diagnosis, treatment, and prognosis of amyloidosis. Research emphasizes transthyretin-related cardiac amyloidosis, light chain amyloidosis, and therapies like patisiran. Growth data over the past 5 years is not available.
Topic Hierarchy
Research Sub-Topics
Transthyretin Cardiac Amyloidosis Diagnosis
This sub-topic covers non-invasive diagnostics like bone scintigraphy, echocardiography strain patterns, and CMR for ATTR cardiac amyloidosis. Researchers validate biomarkers for early detection.
RNAi Therapy for Transthyretin Amyloidosis
This sub-topic evaluates patisiran and vutrisiran in hATTR amyloidosis, focusing on TTR lowering, neuropathy stabilization, and cardiac outcomes. Researchers monitor long-term safety.
Light Chain Amyloidosis Prognosis and Outcomes
This sub-topic analyzes staging systems, hematologic response criteria, and survival predictors in AL amyloidosis. Researchers study organ dysfunction trajectories post-chemotherapy.
Familial Amyloid Polyneuropathy Treatment
This sub-topic investigates TTR stabilizers like tafamidis, liver transplantation, and gene silencers for hATTR-PN. Researchers assess neuropathy progression and quality of life.
Cardiovascular Magnetic Resonance in Amyloidosis
This sub-topic utilizes CMR T1 mapping, ECV quantification, and late gadolinium enhancement for amyloid burden assessment. Researchers correlate imaging with histology and prognosis.
Why It Matters
Amyloidosis research enables diagnosis through techniques like cardiovascular magnetic resonance and treatment with targeted therapies, improving outcomes in specific forms such as hereditary transthyretin amyloidosis. Patisiran, an RNAi therapeutic, improved multiple clinical manifestations including neuropathy and cardiac function in the APOLLO trial (NCT01960348) involving patients with hereditary transthyretin amyloidosis, as shown by Adams et al. (2018) in "Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis" (New England Journal of Medicine, 2745 citations). This addresses immunoglobulin light chain involvement and familial amyloid polyneuropathy, reducing progression in systemic amyloidoses.
Reading Guide
Where to Start
"Protein Misfolding, Functional Amyloid, and Human Disease" by Chiti and Dobson (2006) first, as it provides foundational understanding of amyloid formation mechanisms across diseases, essential before diving into specific diagnostics and treatments.
Key Papers Explained
Chiti and Dobson (2006) in "Protein Misfolding, Functional Amyloid, and Human Disease" establish protein misfolding as the core process (6348 citations), which Kayed et al. (2003) in "Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis" extend to toxic oligomers (4018 citations); this mechanistic base informs therapeutic advances like Adams et al. (2018) in "Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis," targeting transthyretin silencing (2745 citations).
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research centers on transthyretin-related cardiac amyloidosis diagnosis via cardiovascular magnetic resonance and RNAi therapy outcomes, as in patisiran trials, with emphasis on immunoglobulin light chain amyloidosis prognosis; no recent preprints or news available.
Papers at a Glance
Frequently Asked Questions
What causes amyloid formation in diseases like amyloidosis?
Peptides or proteins convert from soluble forms into fibrillar aggregates under certain conditions, leading to pathological states ranging from neurodegenerative disorders to systemic amyloidoses. Chiti and Dobson (2006) in "Protein Misfolding, Functional Amyloid, and Human Disease" identify these transitions as central to amyloid diseases (Annual Review of Biochemistry, 6348 citations).
How does patisiran treat hereditary transthyretin amyloidosis?
Patisiran is an RNAi therapeutic that improved multiple clinical manifestations of hereditary transthyretin amyloidosis in the APOLLO trial (NCT01960348). Adams et al. (2018) in "Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis" reported benefits in neuropathy, quality of life, and cardiac metrics (New England Journal of Medicine, 2745 citations).
What role do soluble amyloid oligomers play in pathogenesis?
Soluble oligomers common to most amyloidoses represent the primary toxic species and share a common conformation-dependent structure. Kayed et al. (2003) in "Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis" demonstrated this structure is unique to oligomers regardless of protein sequence (Science, 4018 citations).
What is the focus of diagnosis in cardiac amyloidosis?
Diagnosis involves identifying transthyretin and light chain amyloid deposits, often using cardiovascular magnetic resonance alongside molecular markers. The cluster highlights transthyretin-related cardiac amyloidosis and immunoglobulin light chain involvement as key diagnostic targets.
How is amyloidosis linked to Alzheimer's disease?
Amyloid beta-protein deposition follows a hierarchical sequence in the brain, expanding anterogradely and relating to Alzheimer's development. Thal et al. (2002) in "Phases of Aβ-deposition in the human brain and its relevance for the development of AD" describe these phases (Neurology, 3315 citations).
Open Research Questions
- ? How can early diagnostic biomarkers distinguish transthyretin cardiac amyloidosis from light chain amyloidosis before irreversible organ damage?
- ? What are the long-term outcomes of RNAi therapies like patisiran in preventing familial amyloid polyneuropathy progression?
- ? Which molecular mechanisms underlie differential prognosis in immunoglobulin light chain versus transthyretin amyloidosis?
- ? How do protein misfolding pathways vary across systemic and localized amyloidosis forms?
- ? What imaging advances, such as cardiovascular magnetic resonance, best predict treatment responses in amyloidosis?
Recent Trends
The field maintains focus on transthyretin-related cardiac amyloidosis, familial amyloid polyneuropathy, and RNAi therapy like patisiran from Adams et al. , with 54,889 total papers; no growth rate over 5 years, no recent preprints, and no news coverage in the last 12 months indicate steady established research.
2018Research Amyloidosis: Diagnosis, Treatment, Outcomes with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Amyloidosis: Diagnosis, Treatment, Outcomes with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers